Vials of Roche's cancer med Herceptin that were stolen in Italy are now showing up in other places in Europe, leading the European Medicines Agency (EMA) to issue an alert and Herceptin maker Roche to recall all of the batches from which the stolen drugs came.
Swiss drug giant Roche has hit the ground running in 2014, announcing today that quick uptake of its new cancer drugs helped drive first-quarter sales up 5% year-over-year in constant currencies to 11.5 billion Swiss francs ($13 billion).
A few months ago Roche put out the word that its schizophrenia drug bitopertin had flunked the first two Phase III studies in a lengthy lineup of clinical trials. And today the pharma giant almost completed its obituary for a drug program that had been touted as one of Roche's top blockbuster prospects, adding a long slate of trial flops to the record.
Just over a month into its search for "strategic options," ThromboGenics has rounded up a bevy of high-dollar offers that could value the company at as much as $1.3 billion, Bloomberg reports, courted by drugmakers who see promise in its underperforming eye drug.
Hospira is one step closer to selling a Herceptin biosimilar in Britain. The U.S.-based drugmaker persuaded a U.K. court to overturn two Roche patents on the drug. And that means, as of now, Herceptin (trastuzumab) could be open to biosim competition when its main patent expires July 28.
Just weeks after Roche released data backing its claim that its hit drug Tamiflu saved lives during the H1N1 swine flu epidemic of 2009, a new study finds no evidence that the product stops the spread of the flu or reduces its complications.
The French Competition Authority has stepped up its probe of potential Lucentis price-fixing. As The Times of London reports, the antitrust regulators said they raided local offices of Roche and Novartis, looking for evidence of collusion.
With seed funding from Atlas Venture and an early-stage partnership with Roche, startup Spero Therapeutics is striking out with a novel approach to drug-resistant bacteria amid an antibiotic sea change in the industry.
pRED has struck its first epigenetics deal, with a $500 million-plus potential payoff for Oryzon and its orphan cancer blocker ORY-1001.
Roche is beefing up its point-of-care molecular diagnostics offerings, signing a deal to acquire Marlborough, MA-based IQuum for $275 million up front and up to $175 million in milestone-based payments.